secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fresh Tracks Therapeutics, Inc. (—)
CIK:        0000819050
Form:       8-K
Filed at:   2023-10-13T23:59:59+00:00
Accession:  0001628280-23-034363
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq to delist Fresh Tracks Therapeutics for being a public shell; company will appeal and pursue liquidation
--------------------------------------------------------------------------------

- Received Nasdaq delisting notice Oct 10; staff determined company is a public shell after discontinuing all clinical programs and terminating most employees.
- Delisting scheduled for Oct 19 unless hearing requested; company will request hearing to stay suspension and delisting.
- Also cited non-compliance with $1.00 minimum bid price rule and lack of independent board/audit/comp committee after board resignations.
- Special meeting of stockholders set for Nov 16 to vote on plan of liquidation and dissolution; if approved, company will file certificate of dissolution.
- Albert N. Marchio, II appointed sole director, CEO, and CFO effective Oct 2 after previous board resigned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/819050/000162828023034363/0001628280-23-034363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/819050/000162828023034363/frtx-20231010.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-034363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer